Research map: BEGEV as Salvage Therapy in Relapsed/Refractory Non-Hodgkin Lymphoma: Real-World Outcomes and Transplantation Feasibility

Back to the article

Papers in this map

  1. Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification · Bruce D. Cheson · 2014 · 5729 citations · Cited by this paper
  2. Balance Rehabilitation in Patients with Traumatic Brain Injury: A Scoping Review · 2026 · Related
  3. Autologous Bone Marrow Transplantation as Compared with Salvage Chemotherapy in Relapses of Chemotherapy-Sensitive Non-Hodgkin's Lymphoma · Thierry O. Philip · 1995 · 2458 citations · Cited by this paper
  4. Short-Term Association of Add-On Gosha-Jinki-Gan with Sleep and Nocturia Outcomes in Patients with Persistent Nocturia Despite Desmopressin: A Real-World Study · 2026 · Related
  5. Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era · Christian Gisselbrecht · 2010 · 1644 citations · Cited by this paper
  6. Angular and Rotational Lower Limb Alignment Variations in Children: Practical Guidance for Paediatricians · 2026 · Related
  7. Randomized Comparison of Gemcitabine, Dexamethasone, and Cisplatin Versus Dexamethasone, Cytarabine, and Cisplatin Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: NCIC-CTG LY.12 · Michael Crump · 2014 · 469 citations · Cited by this paper
  8. Blood Transfusion and ABO Blood Groups in Sickle Cell Disease · 2026 · Related
  9. Survival of Patients With Peripheral T-Cell Lymphoma After First Relapse or Progression: Spectrum of Disease and Rare Long-Term Survivors · Vivien Mak · 2013 · 436 citations · Cited by this paper
  10. Serum YKL-40 in Non-ST-Segment Elevation Acute Coronary Syndrome: A Prospective Exploratory Emergency Department Study · 2026 · Related
  11. Bendamustine (Treanda) Displays a Distinct Pattern of Cytotoxicity and Unique Mechanistic Features Compared with Other Alkylating Agents · Lorenzo M. Leoni · 2008 · 370 citations · Cited by this paper
  12. Circulating miR-221/222 and Serum IL-23 in Treatment-Naïve Multiple Sclerosis: A Case–Control Study · 2026 · Related
  13. Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data · Laurie Helen Sehn · 2021 · 186 citations · Cited by this paper
  14. Association Between Treatment-Emergent Pancreatic Volume Loss and Survival Outcomes in Patients with Metastatic Colorectal Cancer Receiving Bevacizumab · 2026 · Related
  15. Multicenter Phase II Study of Bendamustine Plus Rituximab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma · Ken Ohmachi · 2013 · 171 citations · Cited by this paper
  16. Epidemiological Trends and Clinical Implications: An 8-Year Retrospective Study from a Burn Rehabilitation Center in Taiwan · 2026 · Related
  17. Results From a Prospective, Open-Label, Phase II Trial of Bendamustine in Refractory or Relapsed T-Cell Lymphomas: The BENTLY Trial · Gandhi Laurent Damaj · 2012 · 166 citations · Cited by this paper
  18. A Novel Hemizygous CDX4 Missense Variant Identified in a Taiwanese Man with Severe Teratozoospermia · 2026 · Related
  19. The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project · Monica Bellei · 2018 · 162 citations · Cited by this paper
  20. Comparison of 24 Versus 46-Hour 5-FU Infusion Durations in the Perioperative FLOT Therapy for Gastric Cancer · 2026 · Related
  21. Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma · Jeffrey L. Vacirca · 2013 · 103 citations · Cited by this paper
  22. Bendamustine in Combination With Gemcitabine and Vinorelbine Is an Effective Regimen As Induction Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma: Final Results of a Multicenter Phase II Study · Armando Santoro · 2016 · 103 citations · Cited by this paper
  23. Current and upcoming treatment approaches to common subtypes of PTCL (PTCL, NOS; ALCL; and TFHs) · Alison J. Moskowitz · 2024 · 41 citations · Cited by this paper
  24. Current options and future perspectives in the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma · Fabian Frontzek · 2022 · 38 citations · Cited by this paper
  25. Prognostic Value of FDG PET/CT before Allogeneic and Autologous Stem Cell Transplantation for Aggressive Lymphoma · Gary A. Ulaner · 2015 · 26 citations · Cited by this paper
  26. Efficacy of Salvage Treatments in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Including Chimeric Antigen Receptor T-Cell Therapy: A Systematic Review and Meta-Analysis · Jinchul Kim · 2023 · 13 citations · Cited by this paper
  27. Impact of Implementing a Bendamustine-Based Conditioning Regimen on Outcomes of Autologous Stem Cell Transplantation in Lymphoma while Novel Cellular Therapies Emerge · Silvy Lachance · 2022 · 12 citations · Cited by this paper
  28. Clinical outcomes in transplant‐eligible patients with relapsed or refractory diffuse large B‐cell lymphoma after second‐line salvage chemotherapy: A retrospective study · Yu Yagi · 2023 · 8 citations · Cited by this paper
  29. BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma: a real-life experience · Vittorio Stefoni · 2022 · 4 citations · Cited by this paper
  30. Management of relapsed/refractory DLBCL in the era of novel agents and new approaches · Inna Y. Gong · 2026 · 3 citations · Cited by this paper
  31. Prognostic value of pre-transplantation total metabolic tumor volume on 18fluoro-2-deoxy-d-glucose positron emission tomography–computed tomography in relapsed and refractory aggressive lymphoma · Takeshi Sugio · 2022 · 1 citation · Cited by this paper
  32. Progress in the diagnosis and treatment of diffuse large B-cell lymphoma — State of the art · Anna Czyż · 2025 · 1 citation · Cited by this paper
  33. Real-world treatment patterns and characteristics of patients with diffuse large B-cell lymphoma (DLBCL): a retrospective analysis of US commercial and Medicare claims (2017–2024) · Tycel Phillips · 2026 · 1 citation · Cited by this paper

Source: OpenAlex (CC0)